CAR T collaborations: the next cross-border deal trend?

Multinational companies have been increasingly turning to Chinese biotechs for antibody deals, but CAR T cells could be — and possibly should be — the next opportunity for cross-border collaborations. 

Constructing deal terms to take advantage of both the translational research benefits in China and the market opportunity in the U.S. is slowly emerging as a strategy to advance CAR T cell innovation. On paper, all parties stand to gain...